Author(s):
Suchita Prabhakar Dhamane, Swati Chagdeo Jagdale
Email(s):
spd.jscopr@gmail.com
DOI:
10.5958/0974-360X.2020.00453.9 
Address:
Suchita Prabhakar Dhamane1*, Dr. Swati Chagdeo Jagdale2
1MAEER’s Maharashtra Institute of Pharmacy, Maharashtra, India.
2Professor, Dept of Pharmaceutics, School of Pharmacy, Dr. Vishwanath Karad MIT World Peace University, MIT Campus, Kothrud, Pune, MH, India-411038.
*Corresponding Author
Published In:
Volume - 13,
Issue - 6,
Year - 2020
ABSTRACT:
Rifampicin (RIF) is a semi synthetic derivative of rifamycin B. RIF is crystalline and hydrophobic in nature which may limit therapeutic concentration of RIF at the target site. Crystallanity of RIF can be reduced by formation of nanoparticles. Aim of the present investigation was to develop vanillin crosslinked chitosan nanoparticles of rifampicin by 32 factorial design. Effect of concentration of chitosan and crosslinker on Particle size (PS) and Entrapment efficiency (EE) was studied. PS of nanoparticles was determined by Dynamic Light Scattering method. EE was determined by centrifugation method and free drug was analyzed by UV- visible spectrophotometry. The optimised nanoparticles were characterised by Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), X-Ray Powder Diffractometer (XRPD), scanning electron microscopy and in vitro release study. EE of RIF nanoparticles were found to be in the range of 48.76±0.95 % to 83.24±1.68%. The PSs of the nanoparticles were found to be in the range of 89.63±9.78nm to 436.4±8.44nm. Coefficients of regression equation suggest that PS and EE of chitosan nanoparticles are dependent on concentration of chitosan and vanillin. Optimum experimental conditions were selected based on the overlay plot of PS and EE. Value of average percent error was found to be sufficiently low which confirms the validity of model. FTIR, DSC and XRPD study revealed the formation of nanoparticles. SEM study indicates formation of porous nanoparticles. Results of the study indicate that vanillin can be used as a crosslinker for the preparation of RIF loaded chitosan chitosan nanoparticles.
Cite this article:
Suchita Prabhakar Dhamane, Swati Chagdeo Jagdale. Development of Rifampicin loaded Chitosan nanoparticles by 32 full Factorial design. Research J. Pharm. and Tech 2020; 13(6):2545-2550. doi: 10.5958/0974-360X.2020.00453.9
Cite(Electronic):
Suchita Prabhakar Dhamane, Swati Chagdeo Jagdale. Development of Rifampicin loaded Chitosan nanoparticles by 32 full Factorial design. Research J. Pharm. and Tech 2020; 13(6):2545-2550. doi: 10.5958/0974-360X.2020.00453.9 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-6-3
REFERENCES:
1. WHO (2018) Global Tuberculosis Control. Geneva, Switzerland.
2. WHO (2010) Treatment of tuberculosis guidelines. 4th ed. Switzerland.
3. Mekonnen HS, Mekonnen AWA. Non-adherence to anti-tuberculosis treatment, reasons and associated factors among TB patients attending at Gondar town health centers, Northwest Ethiopia. BMC Research Notes. 2018; 11:691.
4. Henwood SQ, Liebenberg W, Tiedt LR, Lotter AP, Villiers MM. Characterization of the Solubility and Dissolution Properties of Several New RIF Polymorphs, Solvates, and Hydrates. Drug Development and Industrial Pharmacy. 2001; 27(10): 1017–1030.
5. Burgess DJ, Jog R. Pharmaceutical Amorphous Nanoparticles. Journal of Pharmaceutical Sciences 2017;106 (2017): 39-65.
6. Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Design, Development and Therapy. 2016;10: 483–507.
7. Gurnyb R, Peppas N, Felt O, Mayera J, Reista M, Bergera J. Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications. European Journal of Pharmaceutics and Biopharmaceutics. 2004; 57: 19–34.
8. Lopez-Leon T, Carvalho E, Seijo B, Ortega-Vinuesa J, and Bastos-González D Physicochemical characterization of chitosan nanoparticles: electrokinetic and stability behaviour. Journal of Colloid and Interface Science. 2005; 283(2): 344–351.
9. Li PW, Wang G, Yang ZM, Duan W, Peng Z, Kong LS, Wang QH Development of drug-loaded chitosan–vanillin nanoparticles and its cytotoxicity against HT-29 cells. Drug Delivery. 2014;1–6.
10. Xiong H, Peng H, Li J, Xie M, Liu Y, Bai C, Chen L. Vanillin cross-linked chitosan microspheres for controlled release of resveratrol. Food chem. 2010;121(1):23-28.
11. Shang Z, Zhang Y, Shi X, Yu Y, Zhao S, Song H, Chen A. Preparation and Characterization of Vanillin Cross-Linked Chitosan Microspheres of Pterostilbene, International Journal of Polymer Analysis and Characterization. 2014; 19(1): 83-93.
12. Li Y, Zou Q, Li J. Preparation and characterization of vanillin-crosslinked chitosan therapeutic bioactive microcarriers. International Journal of Biological Macromolecules. 2015; 79:736-747.
13. Li QX, Song BZ, Yang ZQ, Fan HL. Preparation and characterization of chitosan microcapsules crosslinked by vanillin. Chinese Journal of Process Engineering. 2006;6(4): 608–613.
14. Valizadeh H, Ghanbarzadeh S, Milani PZ. Application of response surface methodology in development of Sirolimus liposomes prepared by thin film hydration technique. Bioimpacts. 2013; 3(2): 75-81.
15. Gan Q, Wang T, Cochrane C, McCarron P. Modulation of surface charge, particle size and morphological properties of chitosan– TPP nanoparticles intended for gene delivery. Colloids and Surfaces B: Biointerfaces. 2005; 44(2): 65-73.